On November 29, 2022, Codexis, a leading enzyme engineering company in the biotechnology industry, announced a strategic corporate update that included a workforce reduction of approximately 18%. This layoff is part of a plan to prioritize resources on programs with the strongest commercial potential, discontinuing certain internal developments to enhance value and commercial discipline. The restructuring, expected to be largely complete by December 31, 2022, aims to lower operating expenses by about $15 million in 2023 and preserve the company's cash runway through the end of 2024. While the exact number of employees affected wasn't specified, the percentage indicates a significant cut as the company refocuses on high-potential areas for long-term growth.
